annual MeeTIng PResenTeRs - Drug Information Association
annual MeeTIng PResenTeRs - Drug Information Association
annual MeeTIng PResenTeRs - Drug Information Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
DIA 2013 49th Annual Meeting Highlights<br />
ExECutIvE SESSIon:<br />
reinventing the r&d business model: heeding the President’s PCast report<br />
on innovation<br />
tuesday, June 25 | 1:45–3:15 Pm<br />
This session, hosted by the Tufts<br />
Center for the Study of <strong>Drug</strong><br />
Development (CSDD), will examine<br />
how companies across the pharma<br />
sector are transforming their R&D<br />
business models to meet current<br />
and future market demands. This<br />
senior-level session represents the<br />
cross-functional issues that embrace<br />
not just R&D, but preclinical, clinical,<br />
regulatory, operations, portfolio<br />
management, and marketing – all<br />
aspects of business development.<br />
Kenneth i. Kaitin, Phd<br />
Professor and<br />
Director, Center for<br />
the Study of <strong>Drug</strong><br />
DevelopmentTufts<br />
University School of<br />
Medicine<br />
big data: impact on innovation<br />
tuesday, June 25 | 10:15–1:45 Am<br />
With the greater use of electronic<br />
data, access to real-world data on<br />
patients, payers and the health<br />
system is exploding, bringing with it<br />
many opportunities to shape drug<br />
development, commercialization and<br />
access. Many significant initiatives with<br />
broad impact have been undertaken<br />
to shape how these types of data are<br />
being used to guide decision-making.<br />
How are these data being used to<br />
support safety and effectiveness?<br />
Does this information impact the payer<br />
landscape? What are the gaps and<br />
limitations? What are the standards, if<br />
any, available to guide good practice?<br />
robert J. franco, Phd<br />
Principal<br />
PricewaterhouseCoopers<br />
LLP<br />
Kenneth a. Getz, mba<br />
Director of Sponsored<br />
Research<br />
Tufts CSDD; Chairman,<br />
CISCRP;<br />
Tufts University<br />
dalvir Gill, Phd<br />
CEO<br />
TransCelerate<br />
Biopharma Inc<br />
susan dentzer, ma<br />
Former Editor-in-Chief,<br />
Health Affairs;<br />
Senior Policy Advisor<br />
Robert Wood Johnson<br />
Foundation<br />
michael rosenblatt, md<br />
Executive Vice<br />
President and Chief<br />
Medical Officer<br />
Merck & Co., Inc.<br />
rachael fleurence, Phd<br />
Acting Director, PCOR<br />
MethodsPatient<br />
Centered Outcomes<br />
Research Institute<br />
(PCORI)<br />
andy lee, ma<br />
Senior Vice President<br />
Global Clinical<br />
Operations<br />
Genzyme Corporation<br />
bernard munos, mba<br />
Founder<br />
InnoThink<br />
tomasz sablinski, md<br />
Founder and CEO<br />
Transparency Life<br />
Sciences<br />
marc m. boutin, Jd<br />
Executive Vice<br />
President and Chief<br />
Operating Officer<br />
National Health<br />
Council<br />
david w. bates,<br />
md, msc<br />
Senior Vice President<br />
for Quality and Safety<br />
Chief Quality Officer<br />
Brigham and<br />
Women’s Hospital<br />
DIA 2013 49th Annual Meeting | June 23-27 | Boston, MA Register at diahome.org/DIA2013 7
Change language